US FDA: User-Error Risks Grow When OTC Brands Extend With Different Ingredients, Indications
US FDA encourages firms to “identify and avoid potential problems before the product is marketed” by comparing proposed names against the agency’s best practices recommendations and seeking the agency’s input.
